Publications by authors named "Rodrigo Dienstmann"

81Publications

Precision Therapy in RAS Mutant Colorectal Cancer.

Gastroenterology 2020 03 21;158(4):806-811. Epub 2020 Jan 21.

Royal College of Surgeons in Ireland, Dept of Physiology and Medical Physics, RCSI Centre for Systems Medicine, Dublin 2, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.12.051DOI Listing
March 2020

New clinical trial designs in the era of precision medicine.

Mol Oncol 2019 03 22;13(3):549-557. Epub 2019 Feb 22.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396357PMC
March 2019

Precision oncology: separating the wheat from the chaff.

ESMO Open 2018 30;3(6):e000446. Epub 2018 Oct 30.

Hospital Vall d'Hebrón, Oncology Data Science (ODysSey) Group, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://esmoopen.bmj.com/lookup/doi/10.1136/esmoopen-2018-000
Publisher Site
http://dx.doi.org/10.1136/esmoopen-2018-000446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212683PMC
October 2018

Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:231-238

From the Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Catalan Institute of Oncology, Oncobell Program, L'Hospitalet de Llobregat, CIBERONC, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200929
Publisher Site
http://dx.doi.org/10.1200/EDBK_200929DOI Listing
May 2018

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.

Clin Cancer Res 2018 08 17;24(15):3717-3728. Epub 2018 Apr 17.

Department of Experimental and Health Sciences, University Pompeu Fabra, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-3509DOI Listing
August 2018

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Genome Med 2018 03 28;10(1):25. Epub 2018 Mar 28.

Research Program on Biomedical Informatics (GRIB), IMIM Hospital del Mar Medical, Research Institute and Pompeu Fabra University, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-018-0531-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875005PMC
March 2018

Tumor Side as Model of Integrative Molecular Classification of Colorectal Cancer.

Clin Cancer Res 2018 03 21;24(5):989-990. Epub 2017 Dec 21.

Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-3477DOI Listing
March 2018

Cancer: A precision approach to tumour treatment.

Nature 2017 08 19;548(7665):40-41. Epub 2017 Jul 19.

Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature23101DOI Listing
August 2017

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.

Am Soc Clin Oncol Educ Book 2017 ;37:210-215

From the Early Drug Development Unit, Vall d'Hebron University Hospital and Vall d´Hebron Institute of Oncology, CIBERONC, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_180460DOI Listing
December 2017

Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer.

Am Soc Clin Oncol Educ Book 2017 ;37:232-245

From the Dana-Farber Cancer Institute, Boston, MA; Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175660DOI Listing
December 2017

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Nat Rev Cancer 2017 02 4;17(2):79-92. Epub 2017 Jan 4.

Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2016.126DOI Listing
February 2017

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.

Cancer J 2016 May-Jun;22(3):149-55

From the *Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; and †Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000191DOI Listing
January 2017

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

Mol Cancer Ther 2016 05 1;15(5):1106-12. Epub 2016 Apr 1.

Translational Research Laboratory, Catalan Insitute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. Department of Medical Oncology, Catalan Insitute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0820DOI Listing
May 2016

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

J Clin Oncol 2015 Oct 31;33(30):3401-8. Epub 2015 Aug 31.

Josep Tabernero, Rodrigo Dienstmann, Barbara Adamo, and Jordi Rodon, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal; Victor Moreno, START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain; Rastislav Bahleda, Anas Gazzah, and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif; Antoine Italiano, Institut Bergonié, Bordeaux, France; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Alain Mita, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Bob Zhong, Suso J. Platero, Moitreyee Chatterjee-Kishore, Vijay Peddareddigari, and Feng R. Luo, Janssen Research and Development, Raritan, NJ; and Johan W. Smit and Kim Stuyckens, Janssen Research and Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7341DOI Listing
October 2015

Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.

Am Soc Clin Oncol Educ Book 2015 :e149-56

From the Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Medical Oncology, Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e149DOI Listing
February 2016

Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.

J Clin Oncol 2015 Jun 27;33(16):1787-96. Epub 2015 Apr 27.

Rodrigo Dienstmann, Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA; Rodrigo Dienstmann and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; and Ramon Salazar, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0213DOI Listing
June 2015

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

Cancer Chemother Pharmacol 2015 May 27;75(5):1065-73. Epub 2015 Mar 27.

Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2728-5DOI Listing
May 2015

Genomic testing in colorectal cancer: how much is enough?

Oncology (Williston Park) 2015 Mar;29(3):186-8

View Article

Download full-text PDF

Source
March 2015

Intrinsic cancer subtypes--next steps into personalized medicine.

Cell Oncol (Dordr) 2015 Feb 14;38(1):3-16. Epub 2015 Jan 14.

Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Av. Gran Via 199-203, 08907, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13402-014-0203-7DOI Listing
February 2015

Social interactomes for enabling research communities.

Cancer Discov 2014 Nov;4(11):1265-8

Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California. Department of Cell and Molecular Pharmacology, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0774DOI Listing
November 2014

Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.

Mol Oncol 2015 May 15;9(5):940-50. Epub 2014 Jul 15.

Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.06.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528747PMC
May 2015

The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning.

Am Soc Clin Oncol Educ Book 2014 :91-9

From the Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Translational Research Laboratory, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.91DOI Listing
November 2015

TGR analysis in phase I clinical trials--letter.

Clin Cancer Res 2014 May;20(9):2495-6

Authors' Affiliations: Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, Washington and Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3455DOI Listing
May 2014

Standardized decision support in next generation sequencing reports of somatic cancer variants.

Mol Oncol 2014 Jul 4;8(5):859-73. Epub 2014 Apr 4.

Massachusetts General Hospital and Harvard Medical School, Molecular Pathology Lab, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.03.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528527PMC
July 2014

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

Mol Cancer Ther 2014 May 18;13(5):1021-31. Epub 2014 Apr 18.

Authors' Affiliations: Molecular Therapeutics Research Unit, Medical Oncology Department; and Experimental Therapeutics Group, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0639DOI Listing
May 2014

Genomic medicine frontier in human solid tumors: prospects and challenges.

J Clin Oncol 2013 May 15;31(15):1874-84. Epub 2013 Apr 15.

Vall d'Hebron University Hospital, P. Vall d'Hebron 119-122, Barcelona, Spain 08035.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.2268DOI Listing
May 2013

Biomarker-driven patient selection for early clinical trials.

Curr Opin Oncol 2013 May;25(3):305-12

Molecular Therapeutics Research Unit, Medical Oncology Department, Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835ff3cbDOI Listing
May 2013

Development of PI3K inhibitors: lessons learned from early clinical trials.

Nat Rev Clin Oncol 2013 Mar 12;10(3):143-53. Epub 2013 Feb 12.

Medical Oncology Department, Vall d'Hebrón University Hospital, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2013.10
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2013.10DOI Listing
March 2013

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Mol Cancer Ther 2012 Sep 21;11(9):2062-71. Epub 2012 Jun 21.

Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/content/11/9/2062.full.pdf
Web Search
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-12
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-12-0290DOI Listing
September 2012

Panitumumab: a summary of clinical development in colorectal cancer and future directions.

Future Oncol 2012 Apr;8(4):373-89

Medical Oncology Department, Valld'Hebron University Hospital, P. Valld'Hebron, 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.12.20DOI Listing
April 2012

Molecular prescreening to select patient population in early clinical trials.

Nat Rev Clin Oncol 2012 04 3;9(6):359-66. Epub 2012 Apr 3.

Medical Oncology Department, Vall d'Hebrón University Hospital, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2012.48DOI Listing
April 2012

Application of monoclonal antibodies as cancer therapy in solid tumors.

Curr Clin Pharmacol 2012 May;7(2):137-45

Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157488412800228929DOI Listing
May 2012

Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategies.

Am Soc Clin Oncol Educ Book 2012 :168-72

From the Molecular Therapeutics Research Unit, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.74DOI Listing
April 2016

Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.

Mol Oncol 2012 Feb 6;6(1):15-26. Epub 2011 Dec 6.

Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, P Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1016/j.molonc.2011.11.009
Publisher Site
http://dx.doi.org/10.1016/j.molonc.2011.11.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528378PMC
February 2012

Benefit-risk assessment of bevacizumab in the treatment of breast cancer.

Drug Saf 2012 Jan;35(1):15-25

Molecular Therapeutic Research Unit, Medical Oncology Department, Vall dHebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/10.2165/11595910-000000000-00000
Publisher Site
http://dx.doi.org/10.2165/11595910-000000000-00000DOI Listing
January 2012

Development of molecular biomarkers in individualized treatment of colorectal cancer.

Clin Colorectal Cancer 2011 Dec 12;10(4):279-89. Epub 2011 May 12.

Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2011.03.030DOI Listing
December 2011

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.

Expert Opin Biol Ther 2011 Sep 16;11(9):1223-31. Epub 2011 Jun 16.

Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Molecular Therapeutic Research Unit, Medical Oncology Service, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14712598.2011.59
Publisher Site
http://dx.doi.org/10.1517/14712598.2011.595709DOI Listing
September 2011

Personalizing therapy with targeted agents in non-small cell lung cancer.

Oncotarget 2011 Mar;2(3):165-77

Molecular Therapeutic Research Unit, Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260814PMC
http://dx.doi.org/10.18632/oncotarget.245DOI Listing
March 2011

Molecular predictors of response to chemotherapy in colorectal cancer.

Cancer J 2011 Mar-Apr;17(2):114-26

Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318212f844DOI Listing
July 2011

BRAF as a target for cancer therapy.

Anticancer Agents Med Chem 2011 Mar;11(3):285-95

Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/187152011795347469DOI Listing
March 2011

Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.

Oncotarget 2010 Nov;1(7):530-43

Centre for Cancer Research, Monash Institute of Medical Research, Southern Health, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248125PMC
http://dx.doi.org/10.18632/oncotarget.101012DOI Listing
November 2010

Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2.

Recent Pat Anticancer Drug Discov 2011 May;6(2):210-36

Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/157489211795328503DOI Listing
May 2011

Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.

Curr Opin Investig Drugs 2010 Dec;11(12):1434-41

Universitat Autònoma de Barcelona, Vall d'Hebron University Hospital, Medical Oncology Department, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

View Article

Download full-text PDF

Source
December 2010

Palliative percutaneous nephrostomy in recurrent cervical cancer: a retrospective analysis of 50 consecutive cases.

J Pain Symptom Manage 2008 Aug 18;36(2):185-90. Epub 2008 Apr 18.

Division of Clinical Cancer Research, National Cancer Institute, Rio de Janeiro, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2007.09.010DOI Listing
August 2008

Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.

Int Braz J Urol 2007 Sep-Oct;33(5):630-8; discussion 638

Department of Clinical Oncology, National Cancer Institute, Rio de Janeiro, RJ, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/s1677-55382007000500004DOI Listing
September 2008

Evidence-based neoadjuvant endocrine therapy for breast cancer.

Clin Breast Cancer 2006 Oct;7(4):315-20

Medical Oncology, Instituto Nacional de Cancer, Rua Visconde de Santa Isabel, 374/3 Andar, Vila Isabel, CEP 20560-120 Rio de Janeiro, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2006.n.043DOI Listing
October 2006